RecruitingPhase 4NCT05061732

Helicobacter Pylori Eradication and Follow-up

Helicobacter Pylori Eradication and Follow-up in Zhongshan Hospital


Sponsor

Shanghai Zhongshan Hospital

Enrollment

4,447 participants

Start Date

Sep 30, 2021

Study Type

INTERVENTIONAL

Conditions

Summary

This randomized controlled clinical trial will estimate the eradication efficacy of different therapy for Helicobacter pylori treatment. The completion of this trial will expand new therapy for the treatment of Helicobacter pylori, which can not only ensure clinical efficacy, but also reduce the use of antibiotics.


Eligibility

Min Age: 18 YearsMax Age: 75 Years

Inclusion Criteria3

  • Participate in the trial voluntarily, fully understand the trial, and sign the informed consent form (ICF).
  • -75 years old on the day of signing the ICF.
  • Helicobacter pylori infection confirmed by 13C-urea breath test or rapid urease test.

Exclusion Criteria8

  • Patients with severe heart, lung, kidney, liver, blood, nerve, endocrine, and psychiatric diseases.
  • Subjects or guardians refused to participate in the trial.
  • Alcohol and/or drugs Abuse (addiction or dependence) or poor compliance with doctor's judgment.
  • Have taken antibiotics, bismuth, proton pump inhibitors or Chinese traditional medicine 4 weeks before treatment.
  • Pregnant or lactating women.
  • Active peptic ulcer.
  • allergic to drugs used in the trial.
  • any other circumstances that are not suitable for recruitment.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGRabeprazole

20mg bid

DRUGBismuth potassium citrate

0.6g bid

DRUGMetronidazole

0.4g qid

DRUGClarithromycin

0.5g bid

DRUGLevofloxacin

0.5g qd

DRUGAmoxicillin

1g tid

DRUGMetronidazole

0.4g tid

DRUGDoxycycline

0.1g bid

DRUGTetracycline

0.5g qid


Locations(1)

Zhongshan Hospital, Fudan University

Shanghai, Shanghai Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05061732


Related Trials